Publisher
Springer Science and Business Media LLC
Reference145 articles.
1. Levey, A. S. et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, 1–266 (2002).
2. Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1–150 (2013).
3. Bagheri, B. et al. Sodium‐glucose cotransporter 2 inhibitors: a comprehensive review from cells to bedside. Fundam. Clin. Pharmacol. 37, 481–492 (2023).
4. Parfianowicz, D. et al. Finerenone: a new era for mineralocorticoid receptor antagonism and cardiorenal protection. Curr. Probl. Cardiol. 47, 101386 (2022).
5. Fakhouri, F., Schwotzer, N., Golshayan, D. & Frémeaux-Bacchi, V. The rational use of complement inhibitors in kidney diseases. Kidney Int. Rep. 7, 1165–1178 (2022).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献